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Previewsthan conventional therapies. Also, target-
ing fibroblast-cancer cell interactions, by
focusing on ‘‘reversing metabolic asym-
metry,’’ may be a more widely applicable
and successful chemotherapy strategy
for personalized medicine than trying to
develop specific treatments for each in-
dividual molecular target and histologic
subtype of cancer.REFERENCES
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In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation
underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, sug-
gesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate
resistance to PI3K inhibition is warranted.Phosphatidylinositol 3-kinase (PI3K)
regulates cellular proliferation, survival,
and metabolism. PI3K pathway activation
due to aberrant upstream signaling or
mutation of pathway components occurs
in more cancers than any other cellular
signaling pathway. The PIK3CA gene
that encodes the catalytic subunit of
PI3Ka, p110a, is mutated in almost 40%
of breast cancers, and if mutations in
other pathway members that lead to
increased PI3K signaling are included
(e.g., PTEN, PIK3R1-3 and AKT1-3),
more than half of all breast cancers have
at least one PI3K pathway aberration. In
addition, activation of upstream recep-
tor tyrosine kinases, such as occurs
in HER2-positive breast cancers, leads
to increased PI3K signaling. Consistent
with a dependency on PI3K pathwaysignaling, the efficacy of HER2-targeted
therapy is limited by concurrent PI3K
pathway mutations. Similarly, relapse of
estrogen receptor (ER) positive breast
cancers is often associated with constitu-
tive PI3K pathway activation. This has
driven interest in implementing inhibitors
targeting the PI3K pathway into the breast
cancer drug armamentarium. Indeed,
multiple clinical trials are currently evalu-
ating the efficacy of over 30 drugs target-
ing different nodes in the PI3K pathway
in breast and other cancers (https://
clinicaltrials.gov). However, to date, re-
sponses of solid tumors to monotherapy
have been modest and accompanied by
rapid emergence of drug resistance.
The overarching goal for the elucidation
of resistance mechanisms is to facilitate
implementation of rational combinationtherapies that will overcome or prevent
emergence of resistance. Indeed, combi-
nation strategies are beginning to fulfill
the initial excitement that accompanied
the development of PI3K pathway inhibi-
tors. Combination approaches follow two
different strategies. The first approach is
aimed at overcomingPI3Kpathway-medi-
ated resistance to therapeutics targeting
other pathways. For example, combina-
tions of PI3K pathway inhibitors with hor-
mone responsemodifiers in luminal breast
cancer have demonstrated exciting activ-
ity, and, indeed, the allostericmTOR inhib-
itor everolimus has been approved in
combination with the aromatase inhibitor
exemestane for treatment of postmeno-
pausal women with advanced hormone-
receptor positive, HER2-negative breast
cancer (Baselga et al., 2012). A numberell 26, July 14, 2014 ª2014 Elsevier Inc. 7
Figure 1. Rationale for Combinatorial Targeting with PI3K and CDK4/6 Inhibitors
(A) Normal proliferation: under normal growth conditions, signaling through receptor tyrosine kinases to PI3K, AKT, and mTOR leads to cell survival and prolif-
eration, with inhibition of the PI3K pathway leading to cytostasis. TSC1/2 integrates signals from multiple pathways including LKB1/AMPK and RAS/RAF/MEK/
ERK/p90RSK regulatingmTORC1 kinase activity. These inputs can bypass the effects of inhibition of PI3K and AKT onmTOR and contribute to resistance to PI3K
and AKT inhibitors.
(B) PI3Ki resistant cells: cancer cells with acquired or intrinsic resistance to PI3K inhibitors display aberrant activation of downstream signaling components
through activation of mTOR through mechanisms independent of PI3K. These include signals from AMPK, ERK, and p90RSK that converge at TSC1/2 as
well as several other mechanisms. In addition, the estrogen receptor (ER) and likely other mechanisms can activate the CDK4/6-pRB program independent
of mTOR providing a parallel bypass pathway. The parallel bypass pathways allow increases in CyclinD1/CDK4/6 activity, RB phosphorylation, and re-entry
into cell cycle even in the presence of PI3K inhibitors.
(C) Combination of PI3K andCDK4/6 inhibition: combination of PI3K andCDK4/6 inhibitors that can block themultiplemechanisms leading to cyclinD1 andCDK4
activation results in cytostasis of PI3K inhibitor resistant cells.
Cancer Cell
Previewsof trials combining HER2 targeted thera-
pies with PI3K pathway inhibitors to
bypass resistance mediated by mutation
in PI3K pathway members are underway
(https://clinicaltrials.gov). Similarly, com-
binations of PARP and PI3K inhibitors
(PI3Ki) havedemonstratedearlypreclinical
(Juvekar et al., 2012) and clinical suc-
cesses. The secondapproach is to identify
rational drug combinations to overcome
or prevent the emergence of resistance
to PI3K pathway inhibitors. Multiple
studies have described clinically relevant
and potentially targetable adaptive re-
sponses as well as preexisting or ac-
quired genetic resistance mechanisms
that could mediate resistance to
PI3Ki, including downstream activation of
mTOR or MAPK-ERK-RSK pathways,
amplificationofMYC, or increasedexpres-
sion of antiapoptotic Bcl2 family members
(for reviews, see Bagrodia et al., 2012 and
Klempner et al., 2013). Combinatorial tar-
geting of the PI3K pathway and the path-
ways mediating emergent resistance has
eradicated tumor growth in in vitro and
in vivo preclinical studies and is beginning
to show promise in patients.
In this issue of Cancer Cell, Vora et al.
(2014) derive PI3Ki resistant breast can-8 Cancer Cell 26, July 14, 2014 ª2014 Elsevicer cell lines and demonstrate PI3Ki-inde-
pendent cyclinD1/CDK4-dependent RB
phosphorylation (pRB), leading to E2F
dependent cell survival and proliferation
(Figure 1). Indeed, persistent pRB pre-
dicts resistance to PI3Ki in cell lines and
animal models as well as patient trials. In
some cell lines, persistent downstream
signaling is, at least in part, due to incom-
plete PI3K pathway inhibition. A combi-
natorial drug screen with multiple PI3K
mutant breast cancer lines demonstrated
synergy between PI3K and CDK4/6 inhib-
itors that was recapitulated in animal
models. Indeed, in one of four breast
cancer xenograft models, tumors did not
regrow following cessation of therapy.
However, the failure of PI3K and CDK4/6
inhibitor combination therapy in the other
three tumormodels to curemice suggests
that additional biomarkers and poten-
tially alternative drug combinations will
be required to achieve optimal benefit.
Nevertheless, the data argue that persis-
tent expression of cyclin D1 and activa-
tion of CDK4, p-RB, and a downstream
E2F-dependent transcriptional program
enables survival in the presence of PI3Ki
and, further, that combinatorial targeting
of PI3K and CDK4/6 with available inhibi-er Inc.tors may benefit patients, particularly
those that demonstrate persistent p-RB
in the presence of PI3Ki (Figure 1).
Fulvestrant, which downregulates ER
expression, was one of the highest
scoring hits in their drug synergy screen
of two ER-positive PI3Ki resistant cell
lines, consistent with CDK4 activity in
resistant cell lines being dependent on re-
sidual ER signaling (Miller et al., 2011).
Interestingly, ER-positive breast cancers
that have relapsed on ER targeted ther-
apy and subsequently hyperactivated
the PI3K pathway exhibit an ER-depen-
dent but estrogen-independent drug
resistance dependent on activation of
CDK4 and an E2F-induced transcriptional
program. In animal models, the combina-
tion of PI3Ki and ER targeted therapy in-
hibited the CDK4/E2F program, leading
to tumor regression (Miller et al., 2011).
Strikingly, CDK4/6 inhibitors combined
with hormonal response modifiers have
demonstrated promising activity in pa-
tients with ER-positive breast cancer.
Combining this information with the cur-
rent study suggests that targeting PI3K
and CDK4/6 could be effective in ER-pos-
itive breast cancers and could overcome
resistance to ER-targeted therapy.
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PreviewsBecause one of the PI3Ki resistant lines
in the current paper was ER negative,
additional mechanisms likely underlie
persistent CDK4 activation in ER-negative
PI3Ki-resistant breast cancer lines.
Indeed, a comprehensive elucidation of
themechanisms underlying persistent cy-
clin D1 expression and CDK4 activity in
the presence of PI3Ki and the down-
stream events mediating cell survival
and proliferation may provide a ‘‘suite’’
of targets warranting exploration in com-
bination with PI3Ki in the future. In the
absence of a detailed understanding of
the underlying mechanisms, the most
attractive clinical option is to explore the
combination of PI3K and CDK4/6 inhibi-
tors (Figure 1). Direct targeting of CDK4/
6 or critical downstream nodes has the
potential to bypass the multiple resis-
tance mechanisms that integrate at cyclin
D1 expression and CDK4 activation.
The therapeutic implications of the cur-
rent study are promising and warrant
exploration in clinical trials. First, the com-
bination of PI3K and CDK4/6 inhibitors
may be synergistic in different contextsand genomic backgrounds. Second, the
addition of CDK4/6 inhibitors to xenograft
models that progressed on PI3Ki effec-
tively inhibited tumor growth, suggesting
that CDK4/6 inhibitors can prevent the
emergence as well as overcome resis-
tance to PI3Ki. Third, persistent pRB rep-
resents a potential biomarker to identify
patients in which addition of CDK4/6
inhibitors to ongoing PI3Ki treatment
may be beneficial. Fourth, in preclinical
studies, the combination of PI3K and
CDK4/6 inhibitors appears to be well
tolerated. Interestingly, clinical trials are
underway to test the efficacy of CDK4/6
inhibitors together with rapalogs and aro-
matase inhibitors (https://clinicaltrials.
gov) to determine whether the combina-
tion of other PI3K pathway and CDK4/6
inhibitors may benefit patients who have
relapsed on prior hormone or PI3K tar-
geted therapies.
In conclusion, this study adds to the
growing number of rational combinations
with PI3Ki that could fulfill the promise of
targeting the PI3K pathway in the clinic.
Nevertheless, it remains critical to iden-Cancer Ctify and refine biomarkers that will allow
assignment to combination treatments
that would lead to the most efficacious
response and to continue to identify novel
drug combinations that would be well
tolerated in patients.
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The diffuse-type histologic variant of gastric cancer is characterized by highly invasive growth patterns
and lack of cellular cohesion. Two recent studies have identified highly recurrent mutations of the gene
encoding the small GTPase RhoA and suggest that RhoA activity may have a tumor suppressive role in
this disease.Gastric cancer is the third leading cause
of cancer mortality worldwide and,
when diagnosed, carries a dismal prog-
nosis. Although gastric carcinoma has
marked heterogeneity, the two most
salient subtypes are intestinal gastric
cancer (IGC) and diffuse gastric cancer
(DGC). The dichotomization of IGCand DGC emerged following recognition
of their distinct histopathologic growth
patterns. IGC is the more common
variant and typically emerges following
Helicobater pylori infection, which leads
to atrophic gastritis, intestinal meta-
plasia, dysplasia, and finally carcinoma.
Similar to most adenocarcinomas, IGCtypically shows cohesive groups of
tumor cells with a glandular architecture.
DGC, by contrast, owes its name to its
characteristic lack of cellular cohesion,
invasion throughout the stroma, and
poor cellular differentiation (often with a
signet-ring cell morphology). Clinically,
DGC’s propensity for invasion translatesell 26, July 14, 2014 ª2014 Elsevier Inc. 9
